Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab for postprandial hypoglycemia after bariatric surgery
NCT05401578Phase 3Recruiting
- Sponsor
- University Hospital Basel
- Start
- Apr 2023
- Primary completion
- May 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in postprandial hypoglycemia comparing Canakinumab Arm with Placebo Arm (2 arms). Primary endpoints: Change in Health related quality of life (mental health) at Day 90, Change in Health related quality of life (physical health) at Day 90 and 1 more. Started Apr 2023; status: recruiting.
02
Drugs
canakinumab
03
Conditions
postprandial hypoglycemia
Beyond the preview
Go deeper on NCT05401578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05401578.